$BCRX Great we’ve got Imacouk sharing knowledge this morning it’s gona be a good day?
BCRX
+0.12 (1.12%)
10.88
| General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Comparison | ||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
News
...
| ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison | defenseworld.net • |
| BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) | seekingalpha.com • |
| Stocks Rally as Major Indexes Look to End Losing Streaks | schaeffersresearch.com • |
| Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like | uk.sports.yahoo.com • |
| Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? | zacks.com • |
| Why BioCryst Pharmaceuticals Topped the Market Today | fool.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | N/A | N/A | N/A |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
| 2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
| 2022-04-11 | Oppenheimer | Upgrade | Outperform | |
| 2021-12-10 | Oppenheimer | Upgrade | Outperform | |
| 2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
| 2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
| 2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
| 2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
| 2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 85.54M | 2.83% |
| 2022-04-29 | Fidelity Select Portfolios - Biotechnology | 4.19M | 38.95M | 2.26% |
| 2022-04-29 | iShares Russell 2000 ETF | 3.96M | 36.81M | 2.14% |
| 2022-04-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.71M | 34.50M | 2.00% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 38.83M | 1.29% |
| 2022-03-30 | Vanguard Small-Cap Index Fund | 2.25M | 36.59M | 1.21% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
$BCRX Where is this guy mike smith getting subway sandwiches for $4.00 in Dallas there all $5.50.
-
$BCRX Well since my account is going to hell in a hand basket and my family relies on me I’m going to go to my beach house for the week and think about it………now what was I thinking about? Heaven help us all.
-
$BCRX $4.67 how wet it is!
-
$BCRX Wow Mikey this thing is gona take off …run and tell your mommy
-
$BCRX I needed a smile…thanks
-
$BCRX
Who’s it gonna bbbe -
$BCRX Let my people go you raskley rats
-
$BCRX BINGO
-
$BCRX Creatine levels are leveling out …good news
-
‘$BCRX I’m glad to see someone else is concerned about something not just the Sea Turd
-
$BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy
-
$BCRX I think it’s time
-
$BCRX BASTARDS BASTARDS BASTARDS……….
-
$BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.
-
$BCRX You ever felt like you’ve been stabbed in the back…just wondering?
-
-
$BCRX May help control the bleeding…sorry
-
$BCRX @experiment 626 You might have Menorrhagia you might try Neproxen it may help go try the bleeding